NCT06474416View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

March 13, 2026

Conditions
Herpes Simplex Virus Type I Stromal Keratitis
Interventions
GENETIC

BD111 Injection (Investigative New Drug)

BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

COMBINATION_PRODUCT

Triple-drugs therapy of HSV-1 stromal keratitis

"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."

Trial Locations (3)

200000

Huashan Hospital, Fudan University, Shanghai

310009

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Eye Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Shanghai BDgene Co., Ltd.

INDUSTRY